Yahoo! Finance: Biotechnology Industry News: Clovis Oncology’s CO-1686 Continues to Demonstrate Promising Clinical Activity and Safety in Updated Phase I Study Results

Yahoo! Finance: Biotechnology Industry News The latest news on the Biotechnology industry from Yahoo! Finance

The Next Generation in Online Meetings GoTo Webinar is a new, affordable, do-it-yourself Web event service that doesn't require a consultant. Get $10 off after your complimentary trial. From our sponsors

Clovis Oncology's CO-1686 Continues to Demonstrate Promising Clinical Activity and Safety in Updated Phase I Study Results Oct 27th 2013, 23:30 [Business Wire] - Clovis Oncology announced today updated findings from the Phase I portion of its ongoing Phase I/II clinical study of CO-1686, the Company's novel, oral, targeted covalent inhibitor of mutant forms of the epidermal growth factor receptor for the treatment of non-small cell lung cancer in patients with initial activating EGFR mutations as well as the dominant resistance mutation T790M.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions